Seres Therapeutics received FDA input guiding its Phase 2 protocol, concurrent with Nestlé Health Science providing a $25 million installment payment.
2 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Seres Therapeutics received FDA input guiding its Phase 2 protocol, concurrent with Nestlé Health Science providing a $25 million installment payment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Seres Therapeutics received FDA guidance on its Phase 2 protocol and secured a $25M installment from Nestlé Health Science.1 source
Seres Therapeutics successfully navigated FDA requirements, leading to VOWST approval and a sale to Nestlé Health Science.1 source
Keep exploring
The entities involved
-
Seres Therapeutics (United States)
company in Cambridge, United States
Nothing else this week.
- FDA
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireSeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of blo
- GlobeNewswireSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB)